

Proteus mirabilis, Strain 1104843

Catalog No. NR-56702

Product Description:

Proteus mirabilis (*P. mirabilis*), strain 1104843 was isolated in 2014 from a urine sample from a 50-year-old male in Greece. It was deposited as resistant to cefepime, ceftazidime, ceftazidime/avibactam, ceftriaxone, ciprofloxacin, colistin, colistin/P80, doripenem, imipenem, levofloxacin and meropenem. NR-56702 was produced by inoculation of the deposited material into Tryptic Soy broth and grown for 1 day at 37°C in an aerobic atmosphere. The material from the initial growth was passaged in Tryptic Soy broth for 1 day at 37°C in an aerobic atmosphere to produce this lot. Quality control testing was completed under propagation conditions unless otherwise noted.

Lot: 70055815

Manufacturing Date: 08NOV2019

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis Cellular morphology Colony morphology Motility (wet mount)	Gram-negative rods Report results Report results	Gram-negative coccobacilli Circular, entire, translucent and swarming Motile
Genotypic Analysis Sequencing of 16S ribosomal RNA gene	Consistent with <i>P. mirabilis</i>	Consistent with <i>P. mirabilis</i>
Purity (post-freeze) 7 days at 37°C in an aerobic atmosphere on Tryptic Soy agar with 5% defibrinated sheep blood	Growth consistent with expected colony morphology	Growth consistent with expected colony morphology
Viability (post-freeze)	Growth	Growth

/Sonia Bjorum Brower/

Sonia Bjorum Brower

12 DEC 2024

Technical Manager or designee, ATCC Federal Solutions

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

